Guidelines for Prevention and Treatment of Chronic Hepatitis B

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2021 Nov 1

PMID 34722192

Citations 34

Authors

Guiqiang Wang

Zhongping Duan

Affiliations

Soon will be listed here.

Abstract

To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treatment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.

Citing Articles

Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives.

Ugbaja S, Mokoena A, Mushebenge A, Kumalo H, Ngcobo M, Gqaleni N Int J Mol Sci. 2025; 26(4).

PMID: 40003989 PMC: 11855344. DOI: 10.3390/ijms26041523.

The prognosis and immune repertoire characteristics of HBsAg and anti-HBs double positive chronic hepatitis B patients.

Liang H, Wang H, Liang M, Zhang X, Dai M, Li H Clin Exp Med. 2025; 25(1):32.

PMID: 39775320 PMC: 11711149. DOI: 10.1007/s10238-024-01537-3.

Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances.

Cheng J, Shan G, Wan H, Liu Y, Zhang Y, Shi W World J Hepatol. 2025; 16(12):1515-1523.

PMID: 39744198 PMC: 11686541. DOI: 10.4254/wjh.v16.i12.1515.

HBV-Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment.

Tu T, McQuaid T, Jacobson I Liver Int. 2024; 45(1):e16202.

PMID: 39720865 PMC: 11669079. DOI: 10.1111/liv.16202.

Trajectory and predictors of adherence to Nucleos(t)ide analogues medication among patients with chronic hepatitis B.

Zhang L, Tian J, Xu D, Liu Y, Zhang Z Heliyon. 2024; 10(19):e38485.

PMID: 39391516 PMC: 11466648. DOI: 10.1016/j.heliyon.2024.e38485.

References

Hou F, Yin Y, Zeng L, Shang J, Gong G, Pan C . [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2017; 25(8):589-596. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.007. View

Su T, Hu T, Chen C, Huang Y, Chuang W, Lin C . Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016; 36(12):1755-1764. DOI: 10.1111/liv.13253. View

Choi J, Lim Y . Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. J Infect Dis. 2017; 216(suppl_8):S778-S784. DOI: 10.1093/infdis/jix178. View

Gentile G, Andreoni M, Antonelli G, Sarmati L . Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect. 2017; 23(12):916-923. DOI: 10.1016/j.cmi.2017.06.024. View

Liu W, Wang X, Zheng W, Ping L, Zhang C, Wang G . Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016; 57(6):1355-62. DOI: 10.3109/10428194.2015.1116121. View

Cui F, Shen L, Li L, Wang H, Wang F, Bi S . Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017; 23(5):765-772. PMC: 5403029. DOI: 10.3201/eid2305.161477. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Chu C, Liaw Y . Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2011; 54(1):88-90. DOI: 10.1093/cid/cir755. View

Hsu C, Su W, Lee C, Peng C, Chuang W, Kao J . Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018; 117(7):588-597. DOI: 10.1016/j.jfma.2017.12.007. View

10.

DAmico G, Morabito A, DAmico M, Pasta L, Malizia G, Rebora P . New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int. 2017; 12(Suppl 1):34-43. DOI: 10.1007/s12072-017-9808-z. View

11.

Fattovich G . Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003; 23(1):47-58. DOI: 10.1055/s-2003-37590. View

12.

Wong G . Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018; 24(2):108-113. PMC: 6038942. DOI: 10.3350/cmh.2017.0068. View

13.

Wong D, Seto W, Cheung K, Chong C, Huang F, Fung J . Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2016; 37(7):995-1001. DOI: 10.1111/liv.13346. View

14.

Chu C, Liaw Y . Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006; 26(2):142-52. DOI: 10.1055/s-2006-939752. View

15.

Lim Y, Gwak G, Choi J, Lee Y, Byun K, Kim Y . Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol. 2019; 71(1):35-44. DOI: 10.1016/j.jhep.2019.02.021. View

16.

Fattovich G, GIUSTINA G, Schalm S, Hadziyannis S, Almasio P, Christensen E . Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995; 21(1):77-82. DOI: 10.1002/hep.1840210114. View

17.

Sun H, Tang Z, Wang L, Qin L, Ma Z, Ye Q . Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132(7):458-65. DOI: 10.1007/s00432-006-0091-y. View

18.

Chen Y, Liang X, Dai L, Zhang Q, Peng J, Zhu Y . Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis. 2011; 44(1):61-6. DOI: 10.1016/j.dld.2011.08.004. View

19.

Jia W, Song L, Fang Y, Wu X, Liu D, Xu C . Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore). 2014; 93(29):e322. PMC: 4602587. DOI: 10.1097/MD.0000000000000322. View

20.

Hui C, Leung N, Yuen S, Zhang H, Leung K, Lu L . Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007; 46(2):395-401. DOI: 10.1002/hep.21724. View